Comparison of Two Empirical Antimicrobial Therapies of Prosthetic Joint Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

178 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-01

Study Completion Date

2019-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The empirical use of vancomycin in combination with a broad-spectrum beta-lactam is currently recommended after the initial surgery of prosthetic joint infection (PJI). However, the tolerability of such high-dose intravenous regimens is poorly known. T

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

LocalVancomycinPowderToPreventPeriprostheticJointInfection.

NCT05697965

Arthroplasty Complications Periprosthetic Fracture of Hip

UNKNOWN PHASE2

Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection

NCT01757236

Hip Prosthetic Joint Infection

UNKNOWN PHASE2

Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center

NCT03209934

Bone and Joint Infection Treated by Daptomycin

COMPLETED

Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections

NCT03403608

Bone Infection Joint Infection

COMPLETED

Or v IV Antibiotics for Infection

NCT04723940

Joint Infection

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The empirical use of vancomycin in combination with a broad-spectrum beta-lactam is currently recommended after the initial surgery of prosthetic joint infection (PJI). However, the tolerability of such high-dose intravenous regimens is poorly known. The empirical antimicrobial therapy of PJI is associated with an important rate of adverse, linked with the use of the vancomycin and the piperacillin-tazobactam combination. Some studies suggest to use vancomycin-cefepime, which remains to be evaluated in PJI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bone and Joint Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

empirical antibotherapy currently used

patients having had a vancomycin and piperacillin-tazobactam combination as empirical antibiotherapy

empirical antibiotherapy

Intervention Type OTHER

comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies

another empirical antibotherapy

patients having had a vancomycin and cefepime combination as empirical antibiotherapy

empirical antibiotherapy

Intervention Type OTHER

comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

empirical antibiotherapy

comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients having had a prosthetic joint infection and having had a postoperative empirical antibiotherapy with combination of vancomycine and piperacillin-tazobactam or vancomycine and cefepime